Patients had better experiences and fewer problems in health information, care coordination, and psychological and social care.
When Group Health patients received support from a nurse navigator or advocate soon after a cancer diagnosis, they had better experiences and fewer problems with their care-particularly in health information, care coordination, and psychological and social care-according to a randomized controlled trial in the Journal of Clinical Oncology.
“Patients linked with a nurse navigator reported feeling better supported emotionally, more involved in their care, better able to plan ahead, and better informed,” says lead author Ed Wagner, MD, MPH, a senior investigator at Group Health Research Institute and director emeritus of the Institute’s MacColl Center for Health Care Innovation. “They also experienced fewer problems receiving the information and emotional support they needed, and in the coordination of their care.”
Dr. Wagner and colleagues found that following a cancer diagnosis, patients and their families often need extra help with information, translating medical jargon, psychological and social support, and coordinating care from various health providers.
Starting two weeks after the diagnosis, the nurse navigator initiated weekly phone calls and contacted each patient an average of 18 times, including meeting in person at least once with each patient: for example, accompanying them to a doctor’s appointment.
The other group of the patients received “enhanced usual care” consisting of educational material designed by a patient advisory committee. Most (190) of the patients had breast cancer, but 30 had lung and 31 had colon or rectal cancer. Patient-reported outcomes were measured at baseline, four months, and one year.
Some of the differences between the groups persisted for eight months after patients’ last contact with a nurse navigator, suggesting that the nurse navigators helped patients to develop the confidence and skills to manage their illness and treatment more effectively, according to the researchers.
Overall costs of healthcare, including the costs of the intervention, didn’t rise at all with the nurse navigator intervention-and in lung cancer patients, they might have actually declined. No overall changes were detected in patients’ quality of life or depression.
“Many hospitals and cancer centers are already offering navigator programs, but they vary widely in who the navigators are, and what they do,” Dr. Wagner says. “This is the first randomized trial to show a positive impact on patients, and should offer useful information for program development and improvement.”
The oncology nurse navigators had experience with cancer patients, received special training to deal with psychosocial distress, and were familiar with the Group Health system. Group Health has already incorporated an oncology nurse navigator into usual care for women newly diagnosed with breast cancer at its Capitol Hill campus-even before the research was published.
Conversations with Perry and Friends: Saar Mahna, J.D., MBA
July 7th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the "Conversations with Perry and Friends" podcast. In this episode, Cohen speaks with Saar Mahna, J.D., MBA, CEO and founder of Banjo Health, an artificial intelligence company focused on prior authorization.
Listen
Dupixent Is Linked to a Higher Risk of Psoriasis in Patients With Atopic Dermatitis
July 8th 2025AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and psoriasis driven by Th17 inflammation. However, newer research has shown that these diseases can overlap in patients and may even share common pathways.
Read More
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
Autoimmune Diseases Almost Double Mental Health Disorder Risk
July 7th 2025The prevalence of autoimmune disease patients with a mental health disorder is almost twice the number of patients without, suggesting there is a link between inflammation and conditions such as depression, anxiety disorder and bipolar disorder.
Read More
Conversations with Perry and Friends: Saar Mahna, J.D., MBA
July 7th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the "Conversations with Perry and Friends" podcast. In this episode, Cohen speaks with Saar Mahna, J.D., MBA, CEO and founder of Banjo Health, an artificial intelligence company focused on prior authorization.
Listen
Dupixent Is Linked to a Higher Risk of Psoriasis in Patients With Atopic Dermatitis
July 8th 2025AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and psoriasis driven by Th17 inflammation. However, newer research has shown that these diseases can overlap in patients and may even share common pathways.
Read More
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
Autoimmune Diseases Almost Double Mental Health Disorder Risk
July 7th 2025The prevalence of autoimmune disease patients with a mental health disorder is almost twice the number of patients without, suggesting there is a link between inflammation and conditions such as depression, anxiety disorder and bipolar disorder.
Read More
2 Commerce Drive
Cranbury, NJ 08512